Showing results (1-10 of 96) with videos related to
Sort By:
Pageof 10
Expert Opinion on Investigational Drugs|February 28, 2003
Recent advances in the pharmacological treatment of colorectal cancerWells Messersmith, Daniel Laheru, Manuel HidalgoJournal of Alternative and Complementary Medicine (New York, N.Y.)|January 10, 2006
Omega-3 fatty acids for the treatment of cancer cachexia: issues in designing clinical trials of dietary supplementsLindsey Harle, Todd Brown, Daniel Laheru, et al.Cancer Investigation|July 21, 2012
The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreasAni Balmanoukian, Xiaobu Ye, Joseph Herman, et al.Abdominal Radiology (New York)|February 24, 2018
Assessment of iodine uptake by pancreatic cancer following chemotherapy using dual-energy CTSatomi Kawamoto, Matthew K Fuld, Daniel Laheru, et al.International Journal of Clinical and Experimental Pathology|September 12, 2008
Gene expression profiles associated with advanced pancreatic cancerDomenico Campagna, Leslie Cope, Sindhu S Lakkur, et al.Gastrointestinal Cancer Research : GCR|April 4, 2009
Emerging molecular biology of pancreatic cancerRalph H Hruban, Anirban Maitra, Richard Schulick, et al.Cancer|July 10, 2024
Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidenceAmol Gupta, Ana De Jesus-Acosta, Dung Le, et al.Annals of Surgery|October 28, 2016
Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic CancerMarcelo Cerullo, Faiz Gani, Sophia Y Chen, et al.Frontiers in Oncology|September 13, 2023
Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world studyAmol Gupta, Ana De Jesus-Acosta, Lei Zheng, et al.British Journal of Cancer|March 15, 2017
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancerMichael J Pishvaian, Andrew V Biankin, Peter Bailey, et al.Pageof 10